Latest News and Press Releases

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that LIDDS initial five patent families which protect drugs formulated with NanoZolid® technology are now approved in all countries concerned. In...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid®...

JANUARY – DECEMBER 2020 Net sales amounted to MSEK 0.3 (0.0)Operating expenses amounted to MSEK -33.0 (-31.4)Profit/loss before and after tax amounted to MSEK -32.3 (-31.4)Earnings per share amounted...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a collaboration agreement has been signed with the R&D and Production company PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates...

UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical...

STOCKHOLM – LIDDS (Nasdaq First North: LIDDS) announced today that the company will apply for a relisting of its shares from Nasdaq First North to Nasdaq Stockholm Main Market in 2021. LIDDS is...

UPPSALA, SWEDEN – LIDDS AB (publ) A newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will assume the role of Chief Executive Officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior...

JANUARY – SEPTEMBER 2020 Net sales amounted to MSEK 0.0 (0.0)Operating expenses amounted to MSEK -19.8 (-22.9)Profit/loss before and after tax amounted to MSEK -19.8 (-22.9)Earnings per share...